Alkermes (ALKS) Stock Forecast & Price Target

$31.67 +0.22 (+0.70%)

As of 04:00 PM Eastern

Alkermes - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
4

Buy
8

Based on 12 Wall Street analysts who have issued ratings for Alkermes in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 4 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for ALKS.

Consensus Price Target

$38.33
21.04% Upside

According to the 12 analysts' twelve-month price targets for Alkermes, the average price target is $38.33. The highest price target for ALKS is $52.00, while the lowest price target for ALKS is $26.00. The average price target represents a forecasted upside of 21.04% from the current price of $31.67.

Get the Latest News and Ratings for ALKS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alkermes and its competitors.

ALKS Analyst Ratings Over Time

Type	Current Forecast 5/20/24 to 5/20/25	1 Month Ago 4/20/24 to 4/20/25	3 Months Ago 2/20/24 to 2/19/25	1 Year Ago 5/21/23 to 5/20/24
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)	6 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$38.33	$38.50	$37.25	$35.38
Forecasted Upside	21.04% Upside	42.32% Upside	3.93% Upside	45.10% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ALKS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALKS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alkermes Stock vs. The Competition

Type	Alkermes	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	21.04% Upside	4,843.17% Upside	13.03% Upside
News Sentiment Rating	Very Positive News See Recent ALKS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/13/2025	Cantor Fitzgerald 3 of 5 stars	P. Stavropoulos Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/2/2025	HC Wainwright 1 of 5 stars		Reiterated Rating	Neutral ➝ Neutral
5/2/2025	Royal Bank of Canada 3 of 5 stars	L. Timashev Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Perform ➝ Sector Perform	$39.00 ➝ $40.00	+26.16%
5/2/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joel Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$38.00 ➝ $41.00	+34.07%
4/28/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform
3/27/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Hoang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$40.00 ➝ $52.00	+54.35%
2/14/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chris Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$30.00 ➝ $32.00	-11.11%
11/13/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$35.00 ➝ $40.00	+36.85%
11/5/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$25.00 ➝ $36.00	+35.39%
10/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$32.00 ➝ $26.00	-1.44%
Get the Latest News and Ratings for ALKS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.
10/25/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$38.00 ➝ $37.00	+42.09%
6/17/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Thome Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$34.00	+38.78%
4/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$42.00 ➝ $50.00	+87.62%
1/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$27.00 ➝ $29.00	+0.55%
10/24/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	In-Line ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:34 AM ET.

ALKS Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Alkermes is $38.33, with a high forecast of $52.00 and a low forecast of $26.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 4 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares.
: According to analysts, Alkermes's stock has a predicted upside of 21.04% based on their 12-month stock forecasts.
: Over the previous 90 days, Alkermes's stock had 2 upgrades by analysts.
: Alkermes has been rated by research analysts at Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, HC Wainwright, Robert W. Baird, Royal Bank of Canada, and UBS Group in the past 90 days.
: Analysts like Alkermes less than other "medical" companies. The consensus rating score for Alkermes is 2.75 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ALKS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ALKS) was last updated on 5/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alkermes (ALKS) Stock Forecast & Price Target